Compare Jones Lang LaSalle Inc (JLL) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jones Lang LaSalle Inc vs GeneDx Holdings Corp — how do they compare? Jones Lang LaSalle Inc trades at $329.03 (market cap $15.12B), while GeneDx Holdings Corp trades at $60.64 (market cap $1.80B). The key difference: Jones Lang LaSalle Inc is far larger — about 8.4× GeneDx Holdings Corp's market cap, and Jones Lang LaSalle Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| JLL | WGS | |
|---|---|---|
Market Cap | $15.12B | $1.80B |
Sector | Real Estate | Technology |
52-Week High | $358.66 | $167.51 |
52-Week Low | $253.48 | $34.51 |
Enterprise Value | $18.66B | $1.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JLL trades at $325.94, down 1.43% today, but maintains a bullish technical outlook with strong moving average signals. The company shows solid fundamental improvement with revenue growing from $20.9B in 2022 to $26.1B in 2025, while net income margin expanded to 3.35%. Recent earnings beats and positive analyst coverage (54.55% buy rating) support the stock's upward trajectory, with a consensus price target of $405.50 representing 24.4% upside potential.
JLL presents a compelling investment case with improving profitability, strong cash flow generation ($1.19B operating cash flow in 2025), and positive business momentum in commercial real estate services. Key risks include exposure to commercial real estate cycles and potential economic slowdowns, but the company's debt-to-asset ratio improvement to 9.32% and consistent earnings beats provide fundamental support for continued growth.
GeneDx Holdings (WGS) trades at $60.65, down 4.46% amid a bearish technical signal and negative profitability. Recent earnings showed a Q1 2026 miss after two prior beats, with revenue growth but widening losses projected for 2026. The stock faces significant headwinds from multiple securities class action lawsuits alleging misrepresentations, with a deadline of August 3, 2026.
Despite a high analyst buy consensus (90.9%) and a $75.40 price target implying 24% upside, risks are elevated due to litigation, negative margins, and a high EV/EBITDA of 161.17. The upcoming Q2 2026 results on August 3 will be critical for investor confidence, but the legal overhang and fundamental challenges suggest cautious near-term outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
